");vwo_$('head').append(_vwo_sel);return vwo_$('head')[0] && vwo_$('head')[0].lastChild;})("HEAD")}}, R_708874_717_1_2_0:{ fn:function(log,nonce=''){return (function(x) { if(!vwo_$.fn.vwoRevertHtml){ return; }; var ctx=vwo_$(x),el; /*vwo_debug log("Revert","content",""); vwo_debug*/; el=vwo_$('[vwo-element-id="1726583423895"]'); el.revertContentOp().remove();})("HEAD")}}, C_708874_717_1_2_1:{ fn:function(log,nonce=''){return (function(x) {})(".thankyou-msg,.thankyou-msg span,.email-container,.email-sections,.left-section,.right-section,.right-section,#modal-submit, .download-pdf-btn,a.download-pdf-btn,.left-section,.modal-left-input,.modal-left-input-txt,p.agree-checkbox,.frm-heading,.modal-thank-you,div#error-message,.modal-left-cta,.hori-line,.bg-purple,.simplifind-image-placeholder img,.btn-wrapper,.btn-free-trial,.btn-synapse-login,a.btn-synapse-login,div#lead-frm,a.btn-free-trial,.slp-heading,.slp-heading-top,.slp-heading-top2,.para-text,.para-text span,video#syanapseVideo,.syanapseVideo,img.left_img,img.left_img_btm,.slp-heading-blue,.slp-heading-blk,.para-txt-sec-two,.para-txt-sec-three,.frm-sub-heading,.lp_list,.wrapper,.right-section,.frm-heading,.wrapper,.right-section,.email-sections,.left-section,.right-section,.left-section,.right-section,.email-container,.modal-left-input,.modal-left-input-txt,#modal-submit, .download-pdf-btn,a.download-pdf-btn,.para-txt-sec-two, .para-txt-sec-three,.lp_list,.hubs_blk-image,.frm-sub-headin,#hubs_blk-viewToggle,.btn-wrapper,#modal-submit,ul.lp_list li span,ul.lp_list li,.email-container.bg-purple,.margin-top,.features-section-container,.features-section,.features-section h3,.features-section p,.features-section-container,.simplifind-content-container,.simplifind-content-section,.simplifind-image-placeholder,.simplifind-content-section h3,.simplifind-content-section p,.simplifind-content-container,.whyus-container,.whyus-section,.whyus-section h3,.whyus-section p,.whyus-image-placeholder img,.whyus-container,.slp-heading-top2,.top-logo,.btn-wrapper,.slp-heading-blue,.slp-heading-blk, .para-text,.features-section h3,.features-section p,.simplifind-content-section h3,.simplifind-image-placeholder img,.whyus-section h3,.btn-free-trial2,img.left_img_btm,.neo_heading,.btn-free-trial2,.neo_discount_Wrapper,.neo_bg_green,.neo_bg_yellow,.neo_bg_purple,.neo_bg_orange,.neo_containers,.neo_lp_title,.neo_lp_price,.neo_lp_price span,.neo_lp_discount,ul.neo_lp_list,ul.neo_lp_list li,a.neo_download_sample,.neo_border,.neo_heading,.neo_discount_Wrapper")}}, R_708874_717_1_2_1:{ fn:function(log,nonce=''){return (function(x) { if(!vwo_$.fn.vwoRevertHtml){ return; }; })(".thankyou-msg,.thankyou-msg span,.email-container,.email-sections,.left-section,.right-section,.right-section,#modal-submit, .download-pdf-btn,a.download-pdf-btn,.left-section,.modal-left-input,.modal-left-input-txt,p.agree-checkbox,.frm-heading,.modal-thank-you,div#error-message,.modal-left-cta,.hori-line,.bg-purple,.simplifind-image-placeholder img,.btn-wrapper,.btn-free-trial,.btn-synapse-login,a.btn-synapse-login,div#lead-frm,a.btn-free-trial,.slp-heading,.slp-heading-top,.slp-heading-top2,.para-text,.para-text span,video#syanapseVideo,.syanapseVideo,img.left_img,img.left_img_btm,.slp-heading-blue,.slp-heading-blk,.para-txt-sec-two,.para-txt-sec-three,.frm-sub-heading,.lp_list,.wrapper,.right-section,.frm-heading,.wrapper,.right-section,.email-sections,.left-section,.right-section,.left-section,.right-section,.email-container,.modal-left-input,.modal-left-input-txt,#modal-submit, .download-pdf-btn,a.download-pdf-btn,.para-txt-sec-two, .para-txt-sec-three,.lp_list,.hubs_blk-image,.frm-sub-headin,#hubs_blk-viewToggle,.btn-wrapper,#modal-submit,ul.lp_list li span,ul.lp_list li,.email-container.bg-purple,.margin-top,.features-section-container,.features-section,.features-section h3,.features-section p,.features-section-container,.simplifind-content-container,.simplifind-content-section,.simplifind-image-placeholder,.simplifind-content-section h3,.simplifind-content-section p,.simplifind-content-container,.whyus-container,.whyus-section,.whyus-section h3,.whyus-section p,.whyus-image-placeholder img,.whyus-container,.slp-heading-top2,.top-logo,.btn-wrapper,.slp-heading-blue,.slp-heading-blk, .para-text,.features-section h3,.features-section p,.simplifind-content-section h3,.simplifind-image-placeholder img,.whyus-section h3,.btn-free-trial2,img.left_img_btm,.neo_heading,.btn-free-trial2,.neo_discount_Wrapper,.neo_bg_green,.neo_bg_yellow,.neo_bg_purple,.neo_bg_orange,.neo_containers,.neo_lp_title,.neo_lp_price,.neo_lp_price span,.neo_lp_discount,ul.neo_lp_list,ul.neo_lp_list li,a.neo_download_sample,.neo_border,.neo_heading,.neo_discount_Wrapper")}}, R_708874_784_1_2_0:{ fn:function(log,nonce=''){return (function(x) { if(!vwo_$.fn.vwoRevertHtml){ return; }; var ctx=vwo_$(x),el; /*vwo_debug log("Revert","content",""); vwo_debug*/; el=vwo_$('[vwo-element-id="1726583615951"]'); el.revertContentOp().remove();})("HEAD")}}, C_708874_784_1_2_1:{ fn:function(log,nonce=''){return (function(x) {})(".thankyou-msg,.thankyou-msg span,.email-container,.email-sections,.left-section,.right-section,.right-section,#modal-submit, .download-pdf-btn,a.download-pdf-btn,.left-section,.modal-left-input,.modal-left-input-txt,p.agree-checkbox,.frm-heading,.modal-thank-you,div#error-message,.modal-left-cta,.hori-line,.bg-purple,.simplifind-image-placeholder img,.btn-wrapper,.btn-free-trial,.btn-synapse-login,a.btn-synapse-login,div#lead-frm,a.btn-free-trial,.slp-heading,.slp-heading-top,.para-text,video#syanapseVideo,.syanapseVideo,img.left_img,img.left_img_btm,.slp-heading-blue,.slp-heading-blk,.para-txt-sec-two,.para-txt-sec-three,.frm-sub-heading,.lp_list,.wrapper,.right-section,.left-section,.right-section,.email-sections,.email-container,.left-section,.modal-left-input,.modal-left-input-txt,p.agree-checkbox,#modal-submit, .download-pdf-btn,a.download-pdf-btn,.frm-heading,.right-section,.hubs_blk-container,.hubs_blk-row,.hubs_blk-block,.hubs_blk-image,.hubs_blk-heading,.hubs_blk-subheading,.hubs_blk-hidden,#hubs_blk-viewToggle,a.hubs_blk-block,.hubs_blk-block,.hubs_blk-container .hubs_blk-row:nth-child(n+4),.slp-heading-top,.para-txt-sec-two, .para-txt-sec-three,.para-text,.lp_list,.hubs_blk-image,.frm-sub-headin,.slp-heading,#hubs_blk-viewToggle,.btn-wrapper,.slp-heading-blue,.hori-line,#modal-submit,.lp_list,.frm-sub-heading,ul.lp_list li span,ul.lp_list li,.email-container.bg-purple,.margin-top,.features-section-container,.features-section,.features-section h3,.features-section p,.features-section-container,.simplifind-content-container,.simplifind-content-section,.simplifind-image-placeholder,.simplifind-content-section h3,.simplifind-content-section p,.simplifind-content-container,.whyus-container,.whyus-section,.whyus-section h3,.whyus-section p,.whyus-image-placeholder img,.whyus-container,.top-logo,.slp-heading-blk, .para-text,.features-section h3,.features-section p,.simplifind-content-section h3,.simplifind-image-placeholder img,.whyus-section h3")}}, R_708874_784_1_2_1:{ fn:function(log,nonce=''){return (function(x) { if(!vwo_$.fn.vwoRevertHtml){ return; }; })(".thankyou-msg,.thankyou-msg span,.email-container,.email-sections,.left-section,.right-section,.right-section,#modal-submit, .download-pdf-btn,a.download-pdf-btn,.left-section,.modal-left-input,.modal-left-input-txt,p.agree-checkbox,.frm-heading,.modal-thank-you,div#error-message,.modal-left-cta,.hori-line,.bg-purple,.simplifind-image-placeholder img,.btn-wrapper,.btn-free-trial,.btn-synapse-login,a.btn-synapse-login,div#lead-frm,a.btn-free-trial,.slp-heading,.slp-heading-top,.para-text,video#syanapseVideo,.syanapseVideo,img.left_img,img.left_img_btm,.slp-heading-blue,.slp-heading-blk,.para-txt-sec-two,.para-txt-sec-three,.frm-sub-heading,.lp_list,.wrapper,.right-section,.left-section,.right-section,.email-sections,.email-container,.left-section,.modal-left-input,.modal-left-input-txt,p.agree-checkbox,#modal-submit, .download-pdf-btn,a.download-pdf-btn,.frm-heading,.right-section,.hubs_blk-container,.hubs_blk-row,.hubs_blk-block,.hubs_blk-image,.hubs_blk-heading,.hubs_blk-subheading,.hubs_blk-hidden,#hubs_blk-viewToggle,a.hubs_blk-block,.hubs_blk-block,.hubs_blk-container .hubs_blk-row:nth-child(n+4),.slp-heading-top,.para-txt-sec-two, .para-txt-sec-three,.para-text,.lp_list,.hubs_blk-image,.frm-sub-headin,.slp-heading,#hubs_blk-viewToggle,.btn-wrapper,.slp-heading-blue,.hori-line,#modal-submit,.lp_list,.frm-sub-heading,ul.lp_list li span,ul.lp_list li,.email-container.bg-purple,.margin-top,.features-section-container,.features-section,.features-section h3,.features-section p,.features-section-container,.simplifind-content-container,.simplifind-content-section,.simplifind-image-placeholder,.simplifind-content-section h3,.simplifind-content-section p,.simplifind-content-container,.whyus-container,.whyus-section,.whyus-section h3,.whyus-section p,.whyus-image-placeholder img,.whyus-container,.top-logo,.slp-heading-blk, .para-text,.features-section h3,.features-section p,.simplifind-content-section h3,.simplifind-image-placeholder img,.whyus-section h3")}}, R_708874_711_1_2_0:{ fn:function(log,nonce=''){return (function(x) { if(!vwo_$.fn.vwoRevertHtml){ return; }; var ctx=vwo_$(x),el; /*vwo_debug log("Revert","content",""); vwo_debug*/; el=vwo_$('[vwo-element-id="1726583615951"]'); el.revertContentOp().remove();})("HEAD")}}, C_708874_715_1_2_0:{ fn:function(log,nonce=''){return (function(x) {;var _vwo_sel=vwo_$("");vwo_$('head').append(_vwo_sel);return vwo_$('head')[0] && vwo_$('head')[0].lastChild;})("HEAD")}}, R_708874_715_1_2_0:{ fn:function(log,nonce=''){return (function(x) { if(!vwo_$.fn.vwoRevertHtml){ return; }; var ctx=vwo_$(x),el; /*vwo_debug log("Revert","content",""); vwo_debug*/; el=vwo_$('[vwo-element-id="1726583665102"]'); el.revertContentOp().remove();})("HEAD")}}, C_708874_715_1_2_1:{ fn:function(log,nonce=''){return (function(x) {})(".thankyou-msg,.thankyou-msg span,.email-container,.email-sections,.left-section,.right-section,.right-section,#modal-submit, .download-pdf-btn,a.download-pdf-btn,.left-section,.modal-left-input,.modal-left-input-txt,p.agree-checkbox,.frm-heading,.modal-thank-you,div#error-message,.modal-left-cta,.hori-line,.bg-purple,.simplifind-image-placeholder img,.btn-wrapper,.btn-free-trial,.btn-synapse-login,a.btn-synapse-login,div#lead-frm,a.btn-free-trial,.slp-heading,.slp-heading-top,.para-text,video#syanapseVideo,.syanapseVideo,img.left_img,img.left_img_btm,.slp-heading-blue,.slp-heading-blk,.para-txt-sec-two,.para-txt-sec-three,.frm-sub-heading,.lp_list,.wrapper,.right-section,.left-section,.right-section,.email-sections,.email-container,.left-section,.modal-left-input,.modal-left-input-txt,p.agree-checkbox,#modal-submit, .download-pdf-btn,a.download-pdf-btn,.frm-heading,.right-section,.hubs_blk-container,.hubs_blk-row,.hubs_blk-block,.hubs_blk-image,.hubs_blk-heading,.hubs_blk-subheading,.hubs_blk-hidden,#hubs_blk-viewToggle,a.hubs_blk-block,.hubs_blk-block,.hubs_blk-container .hubs_blk-row:nth-child(n+4),.slp-heading-top,.para-txt-sec-two, .para-txt-sec-three,.para-text,.lp_list,.hubs_blk-image,.frm-sub-headin,.slp-heading,#hubs_blk-viewToggle,.btn-wrapper,.slp-heading-blue,.hori-line,#modal-submit,.lp_list,.frm-sub-heading,ul.lp_list li span,ul.lp_list li,.email-container.bg-purple,.margin-top,.features-section-container,.features-section,.features-section h3,.features-section p,.features-section-container,.simplifind-content-container,.simplifind-content-section,.simplifind-image-placeholder,.simplifind-content-section h3,.simplifind-content-section p,.simplifind-content-container,.whyus-container,.whyus-section,.whyus-section h3,.whyus-section p,.whyus-image-placeholder img,.whyus-container,.top-logo,.slp-heading-blk, .para-text,.features-section h3,.features-section p,.simplifind-content-section h3,.simplifind-image-placeholder img,.whyus-section h3")}}, R_708874_715_1_2_1:{ fn:function(log,nonce=''){return (function(x) { if(!vwo_$.fn.vwoRevertHtml){ return; }; })(".thankyou-msg,.thankyou-msg span,.email-container,.email-sections,.left-section,.right-section,.right-section,#modal-submit, .download-pdf-btn,a.download-pdf-btn,.left-section,.modal-left-input,.modal-left-input-txt,p.agree-checkbox,.frm-heading,.modal-thank-you,div#error-message,.modal-left-cta,.hori-line,.bg-purple,.simplifind-image-placeholder img,.btn-wrapper,.btn-free-trial,.btn-synapse-login,a.btn-synapse-login,div#lead-frm,a.btn-free-trial,.slp-heading,.slp-heading-top,.para-text,video#syanapseVideo,.syanapseVideo,img.left_img,img.left_img_btm,.slp-heading-blue,.slp-heading-blk,.para-txt-sec-two,.para-txt-sec-three,.frm-sub-heading,.lp_list,.wrapper,.right-section,.left-section,.right-section,.email-sections,.email-container,.left-section,.modal-left-input,.modal-left-input-txt,p.agree-checkbox,#modal-submit, .download-pdf-btn,a.download-pdf-btn,.frm-heading,.right-section,.hubs_blk-container,.hubs_blk-row,.hubs_blk-block,.hubs_blk-image,.hubs_blk-heading,.hubs_blk-subheading,.hubs_blk-hidden,#hubs_blk-viewToggle,a.hubs_blk-block,.hubs_blk-block,.hubs_blk-container .hubs_blk-row:nth-child(n+4),.slp-heading-top,.para-txt-sec-two, .para-txt-sec-three,.para-text,.lp_list,.hubs_blk-image,.frm-sub-headin,.slp-heading,#hubs_blk-viewToggle,.btn-wrapper,.slp-heading-blue,.hori-line,#modal-submit,.lp_list,.frm-sub-heading,ul.lp_list li span,ul.lp_list li,.email-container.bg-purple,.margin-top,.features-section-container,.features-section,.features-section h3,.features-section p,.features-section-container,.simplifind-content-container,.simplifind-content-section,.simplifind-image-placeholder,.simplifind-content-section h3,.simplifind-content-section p,.simplifind-content-container,.whyus-container,.whyus-section,.whyus-section h3,.whyus-section p,.whyus-image-placeholder img,.whyus-container,.top-logo,.slp-heading-blk, .para-text,.features-section h3,.features-section p,.simplifind-content-section h3,.simplifind-image-placeholder img,.whyus-section h3")}}, C_708874_711_1_2_0:{ fn:function(log,nonce=''){return (function(x) {;var _vwo_sel=vwo_$("");vwo_$('head').append(_vwo_sel);return vwo_$('head')[0] && vwo_$('head')[0].lastChild;})("HEAD")}}, C_708874_790_1_2_0:{ fn:function(log,nonce=''){return (function(x) {;var _vwo_sel=vwo_$("");vwo_$('head').append(_vwo_sel);return vwo_$('head')[0] && vwo_$('head')[0].lastChild;})("HEAD")}}, R_708874_790_1_2_0:{ fn:function(log,nonce=''){return (function(x) { if(!vwo_$.fn.vwoRevertHtml){ return; }; var ctx=vwo_$(x),el; /*vwo_debug log("Revert","content",""); vwo_debug*/; el=vwo_$('[vwo-element-id="1729654085442"]'); el.revertContentOp().remove();})("HEAD")}}, C_708874_790_1_2_1:{ fn:function(log,nonce=''){return (function(x) {})(".thankyou-msg,.thankyou-msg span,.email-container,.email-sections,.left-section,.right-section,.right-section,#modal-submit, .download-pdf-btn,a.download-pdf-btn,.left-section,.modal-left-input,.modal-left-input-txt,p.agree-checkbox,.frm-heading,.modal-thank-you,div#error-message,.modal-left-cta,.hori-line,.bg-purple,.top-logo,.btn-wrapper,.btn-free-trial,.btn-synapse-login,a.btn-synapse-login,div#lead-frm,a.btn-free-trial,.slp-heading,.slp-heading-top,.para-text,video#syanapseVideo,.syanapseVideo,img.left_img,img.left_img_btm,.slp-heading-blue,.slp-heading-blk,.para-txt-sec-two,.para-txt-sec-three,.frm-sub-heading,.lp_list,.wrapper,.team_bg_btm,.hubs_blk-container,.hubs_blk-row,.hubs_blk-block,.hubs_blk-image,.hubs_blk-heading,.hubs_blk-subheading,.hubs_blk-hidden,#hubs_blk-viewToggle,a.hubs_blk-block,.hubs_blk-container .hubs_blk-row:nth-child(n+4),.para-txt-sec-two, .para-txt-sec-three,.frm-sub-headin,#modal-submit,.email-container.bg-purple,.margin-top")}}, R_708874_790_1_2_1:{ fn:function(log,nonce=''){return (function(x) { if(!vwo_$.fn.vwoRevertHtml){ return; }; })(".thankyou-msg,.thankyou-msg span,.email-container,.email-sections,.left-section,.right-section,.right-section,#modal-submit, .download-pdf-btn,a.download-pdf-btn,.left-section,.modal-left-input,.modal-left-input-txt,p.agree-checkbox,.frm-heading,.modal-thank-you,div#error-message,.modal-left-cta,.hori-line,.bg-purple,.top-logo,.btn-wrapper,.btn-free-trial,.btn-synapse-login,a.btn-synapse-login,div#lead-frm,a.btn-free-trial,.slp-heading,.slp-heading-top,.para-text,video#syanapseVideo,.syanapseVideo,img.left_img,img.left_img_btm,.slp-heading-blue,.slp-heading-blk,.para-txt-sec-two,.para-txt-sec-three,.frm-sub-heading,.lp_list,.wrapper,.team_bg_btm,.hubs_blk-container,.hubs_blk-row,.hubs_blk-block,.hubs_blk-image,.hubs_blk-heading,.hubs_blk-subheading,.hubs_blk-hidden,#hubs_blk-viewToggle,a.hubs_blk-block,.hubs_blk-container .hubs_blk-row:nth-child(n+4),.para-txt-sec-two, .para-txt-sec-three,.frm-sub-headin,#modal-submit,.email-container.bg-purple,.margin-top")}}, C_708874_784_1_2_0:{ fn:function(log,nonce=''){return (function(x) {;var _vwo_sel=vwo_$("");vwo_$('head').append(_vwo_sel);return vwo_$('head')[0] && vwo_$('head')[0].lastChild;})("HEAD")}}, C_708874_731_1_2_0:{ fn:function(log,nonce=''){return (function(x) {;var _vwo_sel=vwo_$("");vwo_$('head').append(_vwo_sel);return vwo_$('head')[0] && vwo_$('head')[0].lastChild;})("HEAD")}}, R_708874_731_1_2_0:{ fn:function(log,nonce=''){return (function(x) { if(!vwo_$.fn.vwoRevertHtml){ return; }; var ctx=vwo_$(x),el; /*vwo_debug log("Revert","content",""); vwo_debug*/; el=vwo_$('[vwo-element-id="1726583772520"]'); el.revertContentOp().remove();})("HEAD")}}, C_708874_731_1_2_1:{ fn:function(log,nonce=''){return (function(x) {})(".thankyou-msg,.thankyou-msg span,.email-container,.email-sections,.left-section,.right-section,.right-section,#modal-submit, .download-pdf-btn,a.download-pdf-btn,.left-section,.modal-left-input,.modal-left-input-txt,p.agree-checkbox,.frm-heading,.modal-thank-you,div#error-message,.modal-left-cta,.hori-line,.bg-purple,.simplifind-image-placeholder img,.btn-wrapper,.btn-free-trial,.btn-synapse-login,a.btn-synapse-login,div#lead-frm,a.btn-free-trial,.slp-heading,.slp-heading-top,.slp-heading-top2,.para-text,.para-text span,video#syanapseVideo,.syanapseVideo,img.left_img,img.left_img_btm,.slp-heading-blue,.slp-heading-blk,.para-txt-sec-two,.para-txt-sec-three,.frm-sub-heading,.lp_list,.wrapper,.right-section,.frm-heading,.wrapper,.right-section,.email-sections,.left-section,.right-section,.left-section,.right-section,.email-container,.modal-left-input,.modal-left-input-txt,#modal-submit, .download-pdf-btn,a.download-pdf-btn,.para-txt-sec-two, .para-txt-sec-three,.lp_list,.hubs_blk-image,.frm-sub-headin,#hubs_blk-viewToggle,.btn-wrapper,#modal-submit,ul.lp_list li span,ul.lp_list li,.email-container.bg-purple,.margin-top,.features-section-container,.features-section,.features-section h3,.features-section p,.features-section-container,.simplifind-content-container,.simplifind-content-section,.simplifind-image-placeholder,.simplifind-content-section h3,.simplifind-content-section p,.simplifind-content-container,.whyus-container,.whyus-section,.whyus-section h3,.whyus-section p,.whyus-image-placeholder img,.whyus-container,.slp-heading-top2,.top-logo,.btn-wrapper,.slp-heading-blue,.slp-heading-blk, .para-text,.features-section h3,.features-section p,.simplifind-content-section h3,.simplifind-image-placeholder img,.whyus-section h3,.btn-free-trial2,img.left_img_btm,.neo_heading,.btn-free-trial2,.neo_discount_Wrapper,.neo_bg_green,.neo_bg_yellow,.neo_bg_purple,.neo_bg_orange,.neo_containers,.neo_lp_title,.neo_lp_price,.neo_lp_price span,.neo_lp_discount,ul.neo_lp_list,ul.neo_lp_list li,a.neo_download_sample,.neo_border,.neo_heading,.neo_discount_Wrapper")}}},rules:[{"triggers":["4384053"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.8"}]},{"triggers":["4384179"],"tags":[{"metricId":0,"data":{"campaigns":[{"g":3,"c":8}],"type":"g"},"id":"metric"}]},{"triggers":["1318299"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.14"}]},{"triggers":["4383987"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.531"}]},{"triggers":["1303185"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.2"}]},{"triggers":["9100218"],"tags":[{"metricId":0,"data":{"campaigns":[{"g":6,"c":784}],"type":"g"},"id":"metric"}]},{"triggers":["1303191"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.21"}]},{"triggers":["4010714"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.439"}]},{"triggers":["4384071"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.15"}]},{"triggers":["7620215"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.714"}]},{"triggers":["6435476"],"tags":[{"id":"sampleVisitor","data":{"samplingRate":-2,"priority":4}}]},{"triggers":["4384188"],"tags":[{"metricId":0,"data":{"campaigns":[{"g":6,"c":15}],"type":"g"},"id":"metric"}]},{"triggers":["1303188"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.27"}]},{"triggers":["4010720"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.438"}]},{"triggers":["9100245"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.731"}]},{"triggers":["6435473"],"tags":[{"id":"sampleVisitor","data":{"samplingRate":100,"priority":3}}]},{"triggers":["1318317"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.12"}]},{"triggers":["7620224"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.713"}]},{"triggers":["6465598"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.664"}]},{"triggers":["6435470"],"tags":[{"id":"sampleVisitor","data":{"samplingRate":100,"priority":2}}]},{"triggers":["9100239"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.717"}]},{"triggers":["9100248"],"tags":[{"metricId":0,"data":{"campaigns":[{"g":6,"c":731}],"type":"g"},"id":"metric"}]},{"triggers":["9100221"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.711"}]},{"triggers":["9100224"],"tags":[{"metricId":0,"data":{"campaigns":[{"g":6,"c":711}],"type":"g"},"id":"metric"}]},{"triggers":["6465583"],"tags":[{"id":"sampleVisitor","data":{"samplingRate":-2,"priority":1}}]},{"triggers":["5375710"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.572"}]},{"triggers":["9803118"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.790"}]},{"triggers":["9100215"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.784"}]},{"triggers":["6435389"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.658"}]},{"triggers":["4384176"],"tags":[{"metricId":0,"data":{"campaigns":[{"g":2,"c":7}],"type":"g"},"id":"metric"}]},{"triggers":["1304982"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.28"}]},{"triggers":["9100242"],"tags":[{"metricId":0,"data":{"campaigns":[{"g":6,"c":717}],"type":"g"},"id":"metric"}]},{"triggers":["2198551"],"tags":[{"metricId":281005,"data":{"campaigns":[{"g":7,"c":717}],"type":"m"},"id":"metric"},{"metricId":281005,"data":{"campaigns":[{"g":7,"c":790}],"type":"m"},"id":"metric"},{"metricId":281005,"data":{"campaigns":[{"g":7,"c":731}],"type":"m"},"id":"metric"},{"metricId":281005,"data":{"campaigns":[{"g":7,"c":784}],"type":"m"},"id":"metric"},{"metricId":281005,"data":{"campaigns":[{"g":7,"c":715}],"type":"m"},"id":"metric"},{"metricId":281005,"data":{"campaigns":[{"g":7,"c":711}],"type":"m"},"id":"metric"}]},{"triggers":["3651361"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.399"}]},{"triggers":["9803121"],"tags":[{"metricId":0,"data":{"campaigns":[{"g":6,"c":790}],"type":"g"},"id":"metric"}]},{"triggers":["4384065"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.10"}]},{"triggers":["9100227"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.715"}]},{"triggers":["4384185"],"tags":[{"metricId":0,"data":{"campaigns":[{"g":5,"c":10}],"type":"g"},"id":"metric"}]},{"triggers":["2186101"],"tags":[{"metricId":280303,"data":{"campaigns":[{"g":8,"c":717}],"type":"m"},"id":"metric"},{"metricId":280303,"data":{"campaigns":[{"g":8,"c":790}],"type":"m"},"id":"metric"},{"metricId":280303,"data":{"campaigns":[{"g":8,"c":731}],"type":"m"},"id":"metric"},{"metricId":280303,"data":{"campaigns":[{"g":8,"c":784}],"type":"m"},"id":"metric"},{"metricId":280303,"data":{"campaigns":[{"g":8,"c":715}],"type":"m"},"id":"metric"},{"metricId":280303,"data":{"campaigns":[{"g":8,"c":711}],"type":"m"},"id":"metric"}]},{"triggers":["3051950"],"tags":[{"metricId":382724,"data":{"campaigns":[{"g":5,"c":717}],"type":"m"},"id":"metric"},{"metricId":382724,"data":{"campaigns":[{"g":5,"c":790}],"type":"m"},"id":"metric"},{"metricId":382724,"data":{"campaigns":[{"g":5,"c":731}],"type":"m"},"id":"metric"},{"metricId":382724,"data":{"campaigns":[{"g":5,"c":784}],"type":"m"},"id":"metric"},{"metricId":382724,"data":{"campaigns":[{"g":5,"c":715}],"type":"m"},"id":"metric"},{"metricId":382724,"data":{"campaigns":[{"g":5,"c":711}],"type":"m"},"id":"metric"}]},{"triggers":["3651364"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.417"}]},{"triggers":["6435740"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.660"}]},{"triggers":["4384182"],"tags":[{"metricId":0,"data":{"campaigns":[{"g":4,"c":9}],"type":"g"},"id":"metric"}]},{"triggers":["9100230"],"tags":[{"metricId":0,"data":{"campaigns":[{"g":6,"c":715}],"type":"g"},"id":"metric"}]},{"triggers":["4384059"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.9"}]},{"triggers":["1303206"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.3"}]},{"triggers":["5375884"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.365"}]},{"triggers":["5375707"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.571"}]},{"triggers":["4384047"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.7"}]},{"triggers":["1303446"],"tags":[{"id":"runCampaign","priority":4,"data":"campaigns.20"}]},{"triggers":["8"],"tags":[{"id":"prePostMutation","priority":3},{"priority":2,"id":"groupCampaigns"}]},{"triggers":["9"],"tags":[{"id":"visibilityService","priority":2}]},{"triggers":["2"],"tags":[{"id":"runTestCampaign"}]},{"triggers":["75"],"tags":[{"id":"urlChange"}]},{"triggers":["5"],"tags":[{"id":"checkEnvironment"}]}],pages:{"ec":[{"1709154":{"inc":["o",["url","urlReg","(?i)(http|https)\\:\\\/\\\/www\\.mordorintelligence\\.com\\\/industry-reports\\\/.*"]],"exc":["o",["url","urlReg","(?i)\\\/(market-tends|market-share|companies|news)"]]}},{"1715451":{"inc":["o",["url","urlReg","(?i)(http|https)\\:\\\/\\\/www\\.mordorintelligence\\.com\\\/products\\\/synapse\\?utm_campaign=synapse-landing-page.*$"]]}},{"1779601":{"inc":["o",["url","urlReg","(?i)(http|https)\\:\\\/\\\/www\\.mordorintelligence\\.com\\\/industry-reports\\\/.*"]],"exc":["o",["url","urlReg","(?i)(http|https)\\:\\\/\\\/www\\.mordorintelligence\\.com\\\/industry-reports\\\/.*\\\/buy-now"]]}},{"1041401":{"inc":["o",["url","urlReg","(?i).*\/buy-now"]]}},{"1783918":{"inc":["o",["url","urlReg","(?i)(http|https)\\:\\\/\\\/www\\.mordorintelligence\\.com\\\/market-analysis\\\/.*"]]}},{"1162655":{"inc":["o",["url","urlReg","(?i)(http|https)\\:\\\/\\\/www\\.mordorintelligence\\.com\\\/ja\\\/industry-reports\\\/.*\\\/(market-size|companies)"]]}},{"1140448":{"inc":["o",["url","urlReg","(?i)(http|https)\\:\\\/\\\/www\\.mordorintelligence\\.com\\\/industry-reports\\\/.*"]]}},{"1168585":{"inc":["o",["url","urlReg","(?i)(http|https)\\:\\\/\\\/www\\.mordorintelligence\\.com\\\/industry-reports\\\/.*"]],"exc":["o",["url","urlReg","(?i).*\\\/(market-tends|market-size|market-share|companies|news)"]]}},{"1162646":{"inc":["o",["url","urlReg","(?i)(http|https)\\:\\\/\\\/www\\.mordorintelligence\\.com\\\/industry-reports\\\/.*\\\/(market-size|companies)"]]}},{"1041407":{"inc":["o",["url","urlReg","(?i).*\\\/buy\\-now.*"]]}},{"1041404":{"inc":["o",["url","urlReg","(?i)^.*$"]]}},{"1595151":{"inc":["o",["url","urlReg","(?i)(http|https)\\:\\\/\\\/www\\.mordorintelligence\\.com\\\/products\\\/synapse\\?utm_campaign=free_trial_report_library_september_display.*$"]]}},{"1581804":{"inc":["o",["url","urlReg","(?i).*"]]}},{"1595154":{"inc":["o",["url","urlReg","(?i)(http|https)\\:\\\/\\\/www\\.mordorintelligence\\.com\\\/products\\\/synapse\\?utm_campaign=free_trial_report_library.*$"]]}},{"1595157":{"inc":["o",["url","urlReg","(?i)(http|https)\\:\\\/\\\/www\\.mordorintelligence\\.com\\\/products\\\/synapse\\?utm_campaign=report_library_book_trial_search.*$"]]}},{"1595166":{"inc":["o",["url","urlReg","(?i)(http|https)\\:\\\/\\\/www\\.mordorintelligence\\.com\\\/products\\\/synapse\\?utm_campaign=neo_reports_display.*$"]]}},{"1595169":{"inc":["o",["url","urlReg","(?i)(http|https)\\:\\\/\\\/www\\.mordorintelligence\\.com\\\/products\\\/synapse\\?utm_campaign=neo_reports_search.*$"]]}},{"1697340":{"inc":["o",["url","urlReg","(?i)(http|https)\\:\\\/\\\/www\\.mordorintelligence\\.com\\\/industry-reports\\\/.*\\\/buy-now"]]}}]},pagesEval:{}};if(visMeta){data.dataStore.plugins["GEO"]=visMeta["GEO"];data.dataStore.plugins["UA"]=visMeta["UA"];data.dataStore.plugins["IP"]=visMeta["IP"];data.dataStore.plugins.DACDNCONFIG["DT"]=visMeta["DT"];data.dataStore.plugins.LIBINFO["TRACK"]=visMeta["TRACK"]}return data})(); ;;var commonWrapper=function(argument){if(!argument){argument={valuesGetter:function(){return{}},valuesSetter:function(){},verifyData:function(){return{}}}}var pollInterval=100;var timeout=6e4;return function(){var accountIntegrationSettings={};var _interval=null;function waitForAnalyticsVariables(){try{accountIntegrationSettings=argument.valuesGetter()}catch(error){accountIntegrationSettings=undefined}if(accountIntegrationSettings&&argument.verifyData(accountIntegrationSettings)){argument.valuesSetter(accountIntegrationSettings);return 1}return 0}var currentTime=0;_interval=setInterval((function(){currentTime=currentTime||performance.now();var result=waitForAnalyticsVariables();if(result||performance.now()-currentTime>=timeout){clearInterval(_interval)}}),pollInterval)}}; commonWrapper({valuesGetter:function(){return {"ga4s":0}},valuesSetter:function(data){var singleCall=data["ga4s"]||0;if(singleCall){window.sessionStorage.setItem("vwo-ga4-singlecall",true)}var ga4_device_id="";if(typeof window.VWO._.cookies!=="undefined"){ga4_device_id=window.VWO._.cookies.get("_ga")||""}if(ga4_device_id){window.vwo_ga4_uuid=ga4_device_id.split(".").slice(-2).join(".")}},verifyData:function(data){if(typeof window.VWO._.cookies!=="undefined"){return window.VWO._.cookies.get("_ga")||""}else{return false}}})(); var pushBasedCommonWrapper=function(argument){var firedCamp={};if(!argument){argument={integrationName:"",getExperimentList:function(){},accountSettings:function(){},pushData:function(){}}}return function(){window.VWO=window.VWO||[];var sendDebugLogs=function(expId,variationId,errorType,user_type,data){try{var errorPayload={f:argument["integrationName"]||"",a:window._vwo_acc_id,url:window.location.href,exp:expId,v:variationId,vwo_uuid:window.VWO._&&window.VWO._.cookies&&window.VWO._.cookies.get("_vwo_uuid"),user_type:user_type};if(errorType=="initIntegrationCallback"){errorPayload["log_type"]="initIntegrationCallback";errorPayload["data"]=JSON.stringify(data||"")}else if(errorType=="timeout"){errorPayload["timeout"]=true}if(window.VWO._.customError){window.VWO._.customError({msg:"integration debug",url:window.location.href,lineno:"",colno:"",source:JSON.stringify(errorPayload)})}}catch(e){window.VWO._.customError&&window.VWO._.customError({msg:"integration debug failed",url:"",lineno:"",colno:"",source:""})}};const callbackFn=function(data){if(window._vwo_acc_id===958122||window._vwo_acc_id===900503){sendDebugLogs(0,0,"initIntegrationCallback","",data)}if(!data)return;var expId=data[1],variationId=data[2],repeated=data[0],singleCall=0,debug=0;var experimentList=argument.getExperimentList();var integrationName=argument["integrationName"]||"vwo";if(typeof argument.accountSettings==="function"){var accountSettings=argument.accountSettings();if(accountSettings){singleCall=accountSettings["singleCall"];debug=accountSettings["debug"]}}if(singleCall&&repeated==="vS"||firedCamp[expId]){return}window.expList=window.expList||{};var expList=window.expList[integrationName]=window.expList[integrationName]||[];if(expId&&variationId&&["VISUAL_AB","VISUAL","SPLIT_URL"].indexOf(_vwo_exp[expId].type)>-1){if(experimentList.indexOf(+expId)!==-1){firedCamp[expId]=variationId;var pollInterval=100;var currentTime=0;var timeout=6e4;var user_type=_vwo_exp[expId].exec?"vwo-retry":"vwo-new";var interval=setInterval((function(){if(expList.indexOf(expId)!==-1){clearInterval(interval);return}currentTime=currentTime||performance.now();var toClearInterval=argument.pushData(expId,variationId);if(debug&&toClearInterval){sendDebugLogs(expId,variationId,"",user_type)}var isTimeout=performance.now()-currentTime>=timeout;if(isTimeout&&debug){sendDebugLogs(expId,variationId,"timeout",user_type)}if(toClearInterval||isTimeout){clearInterval(interval)}if(toClearInterval){window.expList[integrationName].push(expId)}}),pollInterval||100)}}};window.VWO.push(["onVariationApplied",callbackFn]);window.VWO.push(["onVariationShownSent",callbackFn])}}; var surveyDataCommonWrapper=function(argument){if(!argument){argument={getCampaignList:function(){return[]},surveyStatusChange:function(){},answerSubmitted:function(){}}}return function(){window.VWO=window.VWO||[];function getValuesFromAnswers(answers){var values=[];for(var i=0;i=timeout;if(toClearInterval||isTimeout){clearInterval(interval)}}),pollInterval)}}window.VWO.push(["onSurveyShown",function(data){commonSurveyCallback(data,argument.surveyStatusChange,"surveyShown")}]);window.VWO.push(["onSurveyCompleted",function(data){commonSurveyCallback(data,argument.surveyStatusChange,"surveyCompleted")}]);window.VWO.push(["onSurveyAnswerSubmitted",function(data){commonSurveyCallback(data,argument.answerSubmitted,"surveySubmitted")}])}}; (function(){var VWOOmniTemp={};window.VWOOmni=window.VWOOmni||{};for(var key in VWOOmniTemp)Object.prototype.hasOwnProperty.call(VWOOmniTemp,key)&&(window.VWOOmni[key]=VWOOmniTemp[key]);window._vwoIntegrationsLoaded=1;pushBasedCommonWrapper({integrationName:"GA4",getExperimentList:function(){return [731,715,709,711,717,784,843,790,828,829,834,831,832,833,835,836,837,838,839,840,846,847]},accountSettings:function(){var accountIntegrationSettings={};if(accountIntegrationSettings["debugType"]=="ga4"&&accountIntegrationSettings["debug"]){accountIntegrationSettings["debug"]=1}else{accountIntegrationSettings["debug"]=0}return accountIntegrationSettings},pushData:function(expId,variationId){var accountIntegrationSettings={};var ga4Setup=accountIntegrationSettings["setupVia"]||"gtag";if(typeof window.gtag!=="undefined"&&ga4Setup=="gtag"){window.gtag("event","VWO",{vwo_campaign_name:window._vwo_exp[expId].name+":"+expId,vwo_variation_name:window._vwo_exp[expId].comb_n[variationId]+":"+variationId});window.gtag("event","experience_impression",{exp_variant_string:"VWO-"+expId+"-"+variationId});return true}return false}})();pushBasedCommonWrapper({integrationName:"GA4-GTM",getExperimentList:function(){return [731,715,709,711,717,784,843,790,828,829,834,831,832,833,835,836,837,838,839,840,846,847]},accountSettings:function(){var accountIntegrationSettings={};if(accountIntegrationSettings["debugType"]=="gtm"&&accountIntegrationSettings["debug"]){accountIntegrationSettings["debug"]=1}else{accountIntegrationSettings["debug"]=0}return accountIntegrationSettings},pushData:function(expId,variationId){var accountIntegrationSettings={};var ga4Setup=accountIntegrationSettings["setupVia"]||"gtm";var dataVariable=accountIntegrationSettings["dataVariable"]||"dataLayer";if(typeof window[dataVariable]!=="undefined"&&ga4Setup=="gtm"){window[dataVariable].push({event:"vwo-data-push-ga4",vwo_exp_variant_string:"VWO-"+expId+"-"+variationId});return true}return false}})(); ;})();(function(){window.VWO=window.VWO||[];var pollInterval=100;var _vis_data={};var intervalObj={};var analyticsTimerObj={};var experimentListObj={};window.VWO.push(["onVariationApplied",function(data){if(!data){return}var expId=data[1],variationId=data[2];if(expId&&variationId&&["VISUAL_AB","VISUAL","SPLIT_URL"].indexOf(window._vwo_exp[expId].type)>-1){}}])})();; ;var vD=VWO.data||{};VWO.data={content:{"fns":{"list":{"vn":1,"args":{"1":{}}}}},as:visMeta["as"],dacdnUrl:"https://dev.visualwebsiteoptimizer.com",accountJSInfo:visMeta["accountJSInfo"]};for(var k in vD){VWO.data[k]=vD[k]};(function(){ try {window._vwoCc={usrExitLimit: 100, disableHeatmapCookieSameSite : true };} catch(e){ } })();var gcpfb=function(a,loadFunc,status,err,success){if(a.indexOf("/cdn/")!==-1){loadFunc(a.replace("cdn/",""),err,success); _vwo_err({message:"Google_Cdn failing for " + a + ". Trying Fallback..",code:"cloudcdnerr",status:status}); return true;}};window.VWO=window.VWO || [];window.VWO._= window.VWO._ || {};window.VWO._.gcpfb=gcpfb;;var fileMeta=window.VWO._.fileMeta;var d={cookie:document.cookie,URL:document.URL,referrer:document.referrer};var w={VWO:{_:{fileMeta}},location:{href:window.location.href,search:window.location.search},_vwoCc:window._vwoCc};window._vwo_cdn="https://dev.visualwebsiteoptimizer.com/cdn/";window._VWO=window._VWO||{};window._VWO.fSeg=["839","836","835","840","709","832","846","833","843","838","847","829","831","828","837","834"];window._VWO.dcdnUrl="/dcdn/settings.js";window._VWO._vis_nc_lib=window._vwo_cdn+"edrv/nc-28d149fb22f837837f6aec93e44d7e46br.js";var loadWorker=function(url){_vwo_code.load(url,{dSC: true, onloadCb: function(xhr,a){window._vwo_wt_l=true;if(xhr.status===200 ||xhr.status===304){var code="var window="+JSON.stringify(w)+",document="+JSON.stringify(d)+";window.document=document;"+xhr.responseText;var blob=new Blob([code||"throw new Error('code not found!');"],{type:"application/javascript"}),url=URL.createObjectURL(blob);window.mainThread={webWorker:new Worker(url)};window.vwoChannelFW=new MessageChannel();window.vwoChannelToW=new MessageChannel();window.mainThread.webWorker.postMessage({vwoChannelToW:vwoChannelToW.port1,vwoChannelFW:vwoChannelFW.port2},[vwoChannelToW.port1, vwoChannelFW.port2]);if(!window._vwo_mt_f)return window._vwo_wt_f=true;_vwo_code.addScript({text:window._vwo_mt_f});delete window._vwo_mt_f}else{if(gcpfb(a,loadWorker,xhr.status)){return;}_vwo_code.finish("&e=loading_failure:"+a)}}, onerrorCb: function(a){if(gcpfb(a,loadWorker)){return;}window._vwo_wt_l=true;_vwo_code.finish("&e=loading_failure:"+a);}})};loadWorker("https://dev.visualwebsiteoptimizer.com/cdn/edrv/" + window.VWO._.fileMeta.workerFile + window.VWO._.fileMeta.workerHash + ".js");;var _vis_opt_file;var _vis_opt_lib;if(window.VWO._.allSettings.dataStore.previewExtraSettings!=undefined&&window.VWO._.allSettings.dataStore.previewExtraSettings.isSurveyPreviewMode){var surveyHash=window.VWO._.allSettings.dataStore.plugins.LIBINFO.SURVEY.HASH;_vis_opt_file="va_survey_debug_events-"+fileMeta.libSuffix+surveyHash+".js";_vis_opt_lib="https://dev.visualwebsiteoptimizer.com/"+_vis_opt_file}else if(window.VWO._.allSettings.dataStore.mode!=undefined&&window.VWO._.allSettings.dataStore.mode=="PREVIEW"){var path1="evad.js?va=";var path2="&d=debugger_new&h=-e03e4e1c1c41065bda7e100da032cb8a";_vis_opt_file=vwoCode.use_existing_jquery&&typeof vwoCode.use_existing_jquery()!=="undefined"?vwoCode.use_existing_jquery()?path1+"vanj"+fileMeta.libSuffix+path2:path1+"va_gq"+fileMeta.libSuffix+path2:path1+fileMeta.visOptFile+path2;_vis_opt_lib="https://dev.visualwebsiteoptimizer.com/"+_vis_opt_file}else{_vis_opt_file=vwoCode.use_existing_jquery&&typeof vwoCode.use_existing_jquery()!=="undefined"?vwoCode.use_existing_jquery()?"edrv/vanj"+fileMeta.libSuffix+fileMeta.vanjFileHash+".js":"edrv/va_gq"+fileMeta.libSuffix+fileMeta.libHash+".js":fileMeta.visOptFile}window._vwo_library_timer=setTimeout((function(){vwoCode.removeLoaderAndOverlay&&vwoCode.removeLoaderAndOverlay();vwoCode.finish()}),vwoCode.library_tolerance&&typeof vwoCode.library_tolerance()!=="undefined"?vwoCode.library_tolerance():2500),_vis_opt_lib=typeof _vis_opt_lib=="undefined"?window._vwo_cdn+_vis_opt_file:_vis_opt_lib;var loadLib=function(url){_vwo_code.load(url, {dSC: true, onloadCb:function(xhr,a){window._vwo_mt_l=true;if(xhr.status===200 || xhr.status===304){if(!window._vwo_wt_f)return window._vwo_mt_f=xhr.responseText;_vwo_code.addScript({text:xhr.responseText});delete window._vwo_wt_f;}else{if(gcpfb(a,loadLib,xhr.status)){return;}_vwo_code.finish("&e=loading_failure:"+a);}}, onerrorCb: function(a){if(gcpfb(a,loadLib)){return;}window._vwo_mt_l=true;_vwo_code.finish("&e=loading_failure:"+a);}})};loadLib(_vis_opt_lib);VWO.load_co=function(u,opts){return window._vwo_code.load(u,opts);};;;}}catch(e){_vwo_code.finish();_vwo_code.removeLoaderAndOverlay&&_vwo_code.removeLoaderAndOverlay();_vwo_err(e);window.VWO.caE=1}})();

Tamanho do mercado de tratamento de hipogonadismo e análise de ações – Tendências e previsões de crescimento (2024 – 2029)

O mercado de tratamento de hipogonadismo é segmentado por tipo (hipogonadismo primário, hipogonadismo central), por tipo de tratamento (terapia de reposição de testosterona, terapia com estrogênio, terapia com progesterona), por via de administração e geografia.

Tamanho do mercado de tratamento de hipogonadismo

mercado de tratamento de hipogonadismo
share button
Período de Estudo 2019 - 2029
Ano Base Para Estimativa 2023
CAGR 3.00 %
Mercado de Crescimento Mais Rápido Ásia-Pacífico
Maior Mercado América do Norte

Principais participantes

Tamanho do mercado de tratamento de hipogonadismo

*Isenção de responsabilidade: Principais participantes classificados em nenhuma ordem específica

Como podemos ajudar?

Análise de mercado de tratamento de hipogonadismo

Espera-se que o Mercado de Tratamento de Hipogonadismo registre um CAGR de 3% durante o período de previsão atribuindo ao aumento da incidência de hipogonadismo, ao aumento da conscientização sobre a doença e suas opções de tratamento e ao crescimento da taxa de infertilidade. Além disso, o alto risco de hipogonadismo na população geriátrica e o grupo de pacientes com diabetes e obesidade também são alguns dos principais impulsionadores do mercado de tratamento de hipogonadismo. Por exemplo, de acordo com um relatório publicado pelo Instituto Nacional de Saúde (NIH), em 2019 a obesidade está a aumentar em todo o mundo e a prevalência de hipogonadismo é significativamente maior em homens com obesidade. Além disso, homens com idade entre 60 e 80 anos apresentam níveis baixos de testosterona em 20% e 80% dos níveis normais de testosterona em homens jovens. Homens acima de 60 anos têm a maior prevalência de hipogonadismo. Assim, os países que aumentam a população geriátrica estão testemunhando uma alta demanda por terapias para tratar o hipogonadismo, impulsionando assim o mercado de hipogonadismo.

Tendências de mercado de tratamento de hipogonadismo

No segmento de tipo de tratamento, espera-se que a terapia de reposição de testosterona testemunhe um crescimento saudável no futuro

Espera-se que a terapia de reposição de testosterona contribua com a maior receita, considerando o fato de que o hipogonadismo é mais prevalente em homens. Várias iniciativas governamentais e aprovações de produtos também estão impulsionando a terapia de reposição de testosterona. Por exemplo, a Clarus Therapeutics, em maio de 2019, recebeu a aprovação da FDA para a testosterona Jatenzo, uma terapia oral de reposição de testosterona para o tratamento de hipogonadismo primário e hipogonadismo hipogonadotrófico em homens. Além disso, a Antares Pharma recebeu a aprovação do FDA em 2018 para a injeção de Xyosted (enantato de testosterona).

Além disso, a taxa decrescente de fertilidade está levando a grandes chances de hipogonadismo e promovendo o crescimento da receita do mercado global.

Participação no mercado de tratamento de hipogonadismo

Espera-se que a América do Norte detenha uma participação significativa no mercado e faça o mesmo no período de previsão

Espera-se que a América do Norte domine o mercado global de tratamento de hipogonadismo durante todo o período de previsão. Esta predominância deve-se principalmente ao aumento dos casos de hipogonadismo, à sensibilização para o distúrbio hormonal, ao aumento da adopção de produtos mais recentes e altamente avançados e à infra-estrutura de saúde avançada. De acordo com o relatório publicado no European Association of Urology Journal no ano de 2017, as tendências de prescrição de testosterona nos Estados Unidos testemunharam um aumento entre 1,8 e 4 vezes nas últimas duas décadas (1997 - 2017), o que está resultando no crescimento de mercado de hipogonadismo.

análise de mercado de tratamento de hipogonadismo

Visão geral da indústria de tratamento de hipogonadismo

O mercado estudado é moderadamente competitivo e existem diversas empresas internacionais presentes neste mercado. Algumas das empresas do mercado são Abbott Laboratories Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Endo International, Ferring Pharmaceuticals, AbbVie Inc.

Líderes de mercado de tratamento de hipogonadismo

  1. Abbott Laboratories Inc

  2. Eli Lilly and Company

  3. Teva Pharmaceutical Industries Ltd

  4. Endo International

  5. Ferring Pharmaceuticals

*Isenção de responsabilidade: Principais participantes classificados em nenhuma ordem específica

Abbott Laboratories Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Endo International, Ferring Pharmaceuticals, AbbVie Inc.
bookmark Precisa de mais detalhes sobre jogadores e concorrentes de mercado?
Baixar amostra

Relatório de mercado de tratamento de hipogonadismo – Índice

  1. 1. INTRODUÇÃO

    1. 1.1 Suposições do estudo

      1. 1.2 Escopo do estudo

      2. 2. METODOLOGIA DE PESQUISA

        1. 3. SUMÁRIO EXECUTIVO

          1. 4. DINÂMICA DE MERCADO

            1. 4.1 Visão geral do mercado

              1. 4.2 Drivers de mercado

                1. 4.2.1 Alto risco de hipogonadismo na população geriátrica

                  1. 4.2.2 Questões de estilo de vida

                  2. 4.3 Restrições de mercado

                    1. 4.3.1 Tabu Social

                    2. 4.4 Análise das Cinco Forças de Porter

                      1. 4.4.1 Ameaça de novos participantes

                        1. 4.4.2 Poder de barganha dos compradores/consumidores

                          1. 4.4.3 Poder de barganha dos fornecedores

                            1. 4.4.4 Ameaça de produtos substitutos

                              1. 4.4.5 Intensidade da rivalidade competitiva

                            2. 5. SEGMENTAÇÃO DE MERCADO

                              1. 5.1 Por tipo

                                1. 5.1.1 Hipogonadismo Primário

                                  1. 5.1.2 Hipogonadismo Central

                                  2. 5.2 Por tipo de tratamento

                                    1. 5.2.1 Terapia de reposição de testosterona

                                      1. 5.2.2 Terapia com Estrogênio

                                        1. 5.2.3 Terapia com Progesterona

                                        2. 5.3 Por Rota de Administração

                                          1. 5.3.1 Gel tópico

                                            1. 5.3.2 Sistema transdérmico

                                              1. 5.3.3 Pelota Implantável

                                                1. 5.3.4 Comprimidos orais

                                                  1. 5.3.5 Outros

                                                  2. 5.4 Por usuário final

                                                    1. 5.4.1 Hospitais

                                                      1. 5.4.2 Clínicas Especializadas

                                                        1. 5.4.3 Outros

                                                        2. 5.5 Geografia

                                                          1. 5.5.1 América do Norte

                                                            1. 5.5.1.1 Estados Unidos

                                                              1. 5.5.1.2 Canadá

                                                                1. 5.5.1.3 México

                                                                2. 5.5.2 Europa

                                                                  1. 5.5.2.1 Alemanha

                                                                    1. 5.5.2.2 Reino Unido

                                                                      1. 5.5.2.3 França

                                                                        1. 5.5.2.4 Itália

                                                                          1. 5.5.2.5 Espanha

                                                                            1. 5.5.2.6 Resto da Europa

                                                                            2. 5.5.3 Ásia-Pacífico

                                                                              1. 5.5.3.1 China

                                                                                1. 5.5.3.2 Japão

                                                                                  1. 5.5.3.3 Índia

                                                                                    1. 5.5.3.4 Austrália

                                                                                      1. 5.5.3.5 Coreia do Sul

                                                                                        1. 5.5.3.6 Resto da Ásia-Pacífico

                                                                                        2. 5.5.4 Médio Oriente e África

                                                                                          1. 5.5.4.1 CCG

                                                                                            1. 5.5.4.2 África do Sul

                                                                                              1. 5.5.4.3 Resto do Médio Oriente e África

                                                                                              2. 5.5.5 América do Sul

                                                                                                1. 5.5.5.1 Brasil

                                                                                                  1. 5.5.5.2 Argentina

                                                                                                    1. 5.5.5.3 Resto da América do Sul

                                                                                                2. 6. CENÁRIO COMPETITIVO

                                                                                                  1. 6.1 Perfis de empresa

                                                                                                    1. 6.1.1 Abbott Laboratories Inc

                                                                                                      1. 6.1.2 Eli Lilly and Company

                                                                                                        1. 6.1.3 Teva Pharmaceutical Industries Ltd

                                                                                                          1. 6.1.4 Endo International

                                                                                                            1. 6.1.5 Ferring Pharmaceuticals

                                                                                                              1. 6.1.6 AbbVie Inc.

                                                                                                                1. 6.1.7 Merck Serono

                                                                                                              2. 7. OPORTUNIDADES DE MERCADO E TENDÊNCIAS FUTURAS

                                                                                                                ** O cenário competitivo abrange visão geral dos negócios, finanças, produtos e estratégias e desenvolvimentos recentes
                                                                                                                bookmark Você pode comprar partes deste relatório. Confira os preços para seções específicas
                                                                                                                Obtenha o detalhamento de preços agora

                                                                                                                Segmentação da indústria de tratamento de hipogonadismo

                                                                                                                O hipogonadismo é um distúrbio hormonal raro caracterizado pela produção insuficiente de testículos ou ovários, resultando na diminuição da produção de hormônios sexuais. O mercado de tratamento de hipogonadismo é segmentado por tipo, tipo de tratamento, via de administração e geografia.

                                                                                                                Por tipo
                                                                                                                Hipogonadismo Primário
                                                                                                                Hipogonadismo Central
                                                                                                                Por tipo de tratamento
                                                                                                                Terapia de reposição de testosterona
                                                                                                                Terapia com Estrogênio
                                                                                                                Terapia com Progesterona
                                                                                                                Por Rota de Administração
                                                                                                                Gel tópico
                                                                                                                Sistema transdérmico
                                                                                                                Pelota Implantável
                                                                                                                Comprimidos orais
                                                                                                                Outros
                                                                                                                Por usuário final
                                                                                                                Hospitais
                                                                                                                Clínicas Especializadas
                                                                                                                Outros
                                                                                                                Geografia
                                                                                                                América do Norte
                                                                                                                Estados Unidos
                                                                                                                Canadá
                                                                                                                México
                                                                                                                Europa
                                                                                                                Alemanha
                                                                                                                Reino Unido
                                                                                                                França
                                                                                                                Itália
                                                                                                                Espanha
                                                                                                                Resto da Europa
                                                                                                                Ásia-Pacífico
                                                                                                                China
                                                                                                                Japão
                                                                                                                Índia
                                                                                                                Austrália
                                                                                                                Coreia do Sul
                                                                                                                Resto da Ásia-Pacífico
                                                                                                                Médio Oriente e África
                                                                                                                CCG
                                                                                                                África do Sul
                                                                                                                Resto do Médio Oriente e África
                                                                                                                América do Sul
                                                                                                                Brasil
                                                                                                                Argentina
                                                                                                                Resto da América do Sul

                                                                                                                Perguntas frequentes sobre pesquisa de mercado sobre tratamento de hipogonadismo

                                                                                                                O Mercado de Tratamento de Hipogonadismo deverá registrar um CAGR de 3% durante o período de previsão (2024-2029)

                                                                                                                Abbott Laboratories Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Endo International, Ferring Pharmaceuticals são as principais empresas que operam no mercado de tratamento de hipogonadismo.

                                                                                                                Estima-se que a Ásia-Pacífico cresça no maior CAGR durante o período de previsão (2024-2029).

                                                                                                                Em 2024, a América do Norte é responsável pela maior participação de mercado no Mercado de Tratamento de Hipogonadismo.

                                                                                                                O relatório abrange o tamanho histórico do mercado de tratamento de hipogonadismo para os anos 2019, 2020, 2021, 2022 e 2023. O relatório também prevê o tamanho do mercado de tratamento de hipogonadismo para os anos 2024, 2025, 2026, 2027, 2028 e 2029.

                                                                                                                Relatório da indústria de tratamento de hipogonadismo

                                                                                                                Estatísticas para a participação de mercado, tamanho e taxa de crescimento de receita do tratamento de hipogonadismo em 2024, criadas por Mordor Intelligence™ Industry Reports. A análise do tratamento de hipogonadismo inclui uma perspectiva de previsão de mercado para 2029 e uma visão histórica. Obtenha uma amostra desta análise do setor como um download gratuito em PDF do relatório.

                                                                                                                close-icon
                                                                                                                80% de nossos clientes procuram relatórios feitos sob medida. Como você quer que adaptemos o seu?

                                                                                                                Por favor, insira um ID de e-mail válido

                                                                                                                Por favor, digite uma mensagem válida!

                                                                                                                Tamanho do mercado de tratamento de hipogonadismo e análise de ações – Tendências e previsões de crescimento (2024 – 2029)